New FDA Approval: Trastuzumab Deruxtecan (TDXd)

Episode
118
Soundcloud
Share

On the heels of accelerated approval by the US FDA, Dr. Stephen Liu discusses trastuzumab-deruxtecan (T-DXd) with medical oncologists and clinical investigators, Dr. Lyudmila Bazhenova, from the University of California, San Diego, and Dr. Julian Mazieres, from Toulouse University Hospital. T-DXd is an antibody-drug conjugate now approved for the treatment of HER2-mutant NSCLC, and in this episode, its design, efficacy, and safety are reviewed.

Guest
Stephen Liu, MD
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Lyudmila Bazhenova
Lyudmila Bazhenova

MD

Professor of Medicine
University of California
Julien Mazieres
Julien Mazières

MD

Professor of Pulmonary Medicine
Toulouse University Hospital
Paul Sabatier University

Other Podcast

Climate Change & Lung Cancer Part 2
Episode
132
Evolution of stage III NSCLC
Episode
131
LCC 11-8 V2
Episode
130
Lung Cancer Care in Rural US
Episode
129